EXCERPT

04/22/2023 Press releases

CHEPLAPHARM announces that it has agreed on 21^st April with Eli Lilly and Company on the acquisition of the worldwide[1] commercial rights for Zyprexa^®. The subject of the transaction is the well-established and positioned olanzapine/olanzapine pamoate monohydrate (“OPM”) portfolio consisting of ZypAdhera^® / Relprevv (depot IM[2]), Zyprexa^® IM² (IM), Zyprexa^® Zydis / Zyprexa^® Velotab (ODT form), and Zyprexa^® (oral form, tablets). These products are indicated for the treatment of schizophrenia and bipolar disorders.

As a leading acquirer of originator brands from big pharma companies, CHEPLAPHARM has built up a strong and diversified portfolio of well-established medicines over the last 20 years. “I am very excited about announcing the acquisition of this attractive portfolio and look forward to a successful closing of the transaction with Lilly”, says Edeltraud Lafer, CEO of CHEPLAPHARM. “This acquisition strengthens our portfolio in the therapeutic area of the central nervous system and represents a further milestone in CHEPLAPHARM’s success story. It demonstrates our ability to manage increasingly bigger deals, while our deep and long-standing experience makes me quite confident that we will be able to ensure an efficient and seamless integration as well. This opens completely new opportunities for the future.”

Read full news release here.